Leukemia Cell Models for Research

Leukemia is a group of hematologic malignancies characterized by abnormal proliferation of leukocytes. According to the World Health Organization (WHO) GLOBOCAN 2022 data, leukemia accounted for approximately 474,000 new cases and 311,000 deaths globally, representing about 2.4% of all cancer cases and 3.1% of cancer deaths. The incidence varies by subtype, with acute myeloid leukemia (AML) being the most common acute leukemia in adults, and acute lymphoblastic leukemia (ALL) being the most common in children. The National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) program reports a 5-year relative survival rate of about 65% for all leukemias combined (2013-2019), but this varies significantly by subtype: chronic lymphocytic leukemia (CLL) has a 5-year survival of 87%, while acute myeloid leukemia (AML) has a 5-year survival of only 30%. Risk factors include ionizing radiation, benzene exposure, smoking, certain chemotherapy agents, and genetic predispositions such as Down syndrome, Li-Fraumeni syndrome, and familial mutations in genes like CEBPA and RUNX1.

Leukemia is an ideal model for studying cancer biology due to its accessibility (blood and bone marrow samples), well-defined subtypes, and extensive molecular characterization. Public datasets such as The Cancer Genome Atlas (TCGA) for AML (LAML) and the COSMIC database provide comprehensive genomic, transcriptomic, and epigenetic data. Open questions include the mechanisms of therapy resistance, the role of clonal heterogeneity, and the identification of novel therapeutic targets. Gene-edited cell models enable functional validation of these findings, making them essential for translational research.

Leukemogenesis involves multiple pathways that drive uncontrolled proliferation, differentiation block, and resistance to apoptosis. Key pathways include:

• • JAK-STAT pathway: Constitutive activation via mutations in JAK2, JAK3, or FLT3 leads to uncontrolled cell growth.
• • PI3K/AKT/mTOR pathway: Hyperactivation promotes survival and proliferation.
• • MAPK/ERK pathway: Mutations in RAS family genes (NRAS, KRAS) or upstream receptors (KIT, FLT3) drive sustained signaling.
• • Apoptosis regulation: Mutations in TP53 or BCL2 family members impair programmed cell death.
• • Steps in leukemogenesis often involve:

1. Acquisition of a driver mutation (e.g., chromosomal translocations like BCR-ABL1 in CML).

2. Secondary mutations (e.g., FLT3-ITD, NPM1) that enhance proliferation.

3. Clonal evolution and selection under therapy pressure.

The following table summarizes high-frequency genetic alterations in leukemia based on TCGA and COSMIC data:

Leukemia cells exhibit deregulation of multiple signaling networks that interact to promote malignancy. Key networks include:

• • Wnt/β-catenin pathway: Overactivation leads to increased self-renewal of leukemic stem cells.
• • Notch signaling: Especially in T-ALL, mutations in NOTCH1 lead to constitutive activation.
• • Hedgehog pathway: Involved in leukemic stem cell maintenance.
• • NF-κB pathway: Chronic inflammation and survival signals.
• • Key nodes in these networks include:
• • β-catenin (CTNNB1)
• • NOTCH1
• • SMO and GLI1 (Hedgehog)
• • IKK complex and RELA (NF-κB)

Targeting these nodes with inhibitors is an active area of drug development.

Commonly used leukemia cell lines include:

Organoid models for leukemia are less common than for solid tumors, but 3D co-culture systems with stromal cells have been developed to mimic the bone marrow niche. These models preserve cell-cell interactions and drug response profiles better than 2D cultures.

Animal models are essential for studying leukemia in vivo. Examples include:

• • Patient-derived xenografts (PDX): Immunodeficient mice (e.g., NSG) engrafted with patient leukemia cells. They retain the genetic heterogeneity of the original tumor.
• • Genetically engineered mouse models (GEMM): Knock-in of oncogenes (e.g., MLL-AF9, BCR-ABL1) or knockout of tumor suppressors (e.g., TP53) to recapitulate human leukemia.
• • Induced models: Use of viral vectors to express oncogenes in mouse hematopoietic stem cells followed by transplantation.

These models are used for preclinical drug testing and studying leukemia-initiating cells.

CRISPR-based gene editing has revolutionized the generation of isogenic cell models. By introducing precise knockouts (e.g., TP53, DNMT3A) or knock-ins (e.g., FLT3-ITD, BCR-ABL1) into leukemia cell lines, researchers can study the functional impact of specific mutations in a controlled genetic background. These models are commercially available from various sources and are sequence-verified to ensure accuracy. They enable:

• • Functional validation of driver mutations.
• • Drug screening in isogenic pairs (mutant vs. wild-type).
• • Identification of synthetic lethal interactions.

Commercially available, sequence-verified gene-edited cell lines accelerate research by eliminating the time-consuming process of generating and validating edited clones.

Gene-edited leukemia cell lines are powerful tools for functional genomics. For example:

• • Knockout of TP53 in K562 cells (which already have a TP53 null background) can be used to study p53-independent pathways.
• • Knock-in of FLT3-ITD in MV4-11 cells (which already have FLT3-ITD) allows comparison with isogenic FLT3-wild-type cells to identify FLT3-dependent vulnerabilities.
• • Knockout of DNMT3A in hematopoietic stem cells can model clonal hematopoiesis and its progression to leukemia.

These models help validate candidate genes from genome-wide screens and elucidate gene function.

Isogenic cell line pairs (e.g., mutant vs. wild-type for a specific gene) are ideal for drug screening. For instance:

• • FLT3-ITD knock-in cells can be used to screen FLT3 inhibitors (e.g., midostaurin, gilteritinib) and identify resistance mechanisms.
• • BCR-ABL1 knock-in models help study resistance to tyrosine kinase inhibitors (e.g., imatinib) and test next-generation inhibitors.
• • TP53 knockout cells can be used to assess the efficacy of drugs that rely on p53 function.

Resistance models can be generated by chronic drug exposure, and gene editing can be used to introduce specific resistance mutations (e.g., T315I in BCR-ABL1).

CRISPR-based synthetic lethality screens using gene-edited leukemia cell lines can identify novel biomarkers and therapeutic targets. For example:

• • Screens in FLT3-ITD cells can identify genes that are essential only in the presence of the mutation, revealing potential drug targets.
• • Knockout of DNA repair genes (e.g., PARP1) in TP53-mutant cells can identify vulnerabilities that can be exploited therapeutically.

These approaches accelerate precision medicine by linking genetic alterations to therapeutic responses.

The following databases provide valuable data for leukemia research: